Top segments and regional performance

Last year, the company generated ‪9.21 B‬ DKK, the most of which — ‪9.21 B‬ DKK — came from its top-performing segment, Peptide-based Medicines, compared to ‪62.69 M‬ DKK the previous year. The greatest contribution came from Switzerland, which accounted for ‪9.18 B‬ DKK last year.